Precision BioSciences Inc (FRA:PBS0)
€ 9.85 -0.25 (-2.48%) Market Cap: 65.13 Mil Enterprise Value: -34.23 Mil PE Ratio: 0 PB Ratio: 2.02 GF Score: 56/100

Precision BioSciences Inc Announces In Vivo Gene Editing Collaboration with Novatris Transcript

Jun 22, 2022 / 12:00PM GMT
Release Date Price: €49.92 (+38.15%)
Operator

Good day. And thank you for standing by. Welcome to the Precision Biosciences in vivo gene editing collaboration with Novartis. (Operator Instructions). Please be advised that today's conference may be recorded. I would now like to hand the conference over to your speaker today, Alex Kelly, Chief Financial Officer, please go ahead.

Alex Kelly
Chief Financial Officer - Precision Biosciences

Thank you, [Catherine]. And good morning, everyone. And welcome to our webcast to discuss our recently announced in vivo gene editing collaboration with Novartis and the financing that we completed yesterday, which together extend our cash runway to the end of 2024.

Before we begin, I'd like to remind you that the statements we make today on this webcast that do not relate to material -- relate to matters of historical fact, our future expectations, and forward-looking statements.

Our forward looking statements are within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot